New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
07:35 EDTNVS, ALNYAlnylam outlook not affected by Novartis decision, says JMP Securities
After Novartis (NVS) discontinued its RNAi drug discovery program, JMP Securities does not think the decision should affect the potential of Alnylam's (ALNY) pipeline. The firm believes that Novartis' inability to figure out RNAi technology - and not problems with RNAi as a whole - led to Nvoartis' decision. The firm reiterates a $110 price target and Outperform rating on Alnylam.
News For ALNY;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
07:06 EDTNVSBioLineRx and Novartis enter into strategic collaboration agreement
Subscribe for More Information
05:48 EDTNVSNovartis gains FDA approval for Signifor LAR
Subscribe for More Information
December 15, 2014
08:42 EDTALNYAlnylam price target raised to $125 from $105 at Leerink
Subscribe for More Information
06:06 EDTALNYAlnylam price target raised to $158 from $134 at Piper Jaffray
Subscribe for More Information
December 12, 2014
10:01 EDTALNYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:36 EDTNVSNovartis reports BOLERO-1 trial did not meet primary objective
Subscribe for More Information
07:05 EDTALNYAlnylam sees filing IND for ALN-HBV DC program in late 2015
Subscribe for More Information
07:03 EDTALNYAlnylam sees initial data from ALN-PCSsc trial in mid-2015
Subscribe for More Information
07:02 EDTALNYAlnylam updates guidance to file clinical trial application for ALN-AS1
Subscribe for More Information
05:31 EDTNVSNovartis reports Cosentyx 'superior' in head-to-head psoriasis study
Subscribe for More Information
05:30 EDTALNYAlnylam initiated with a Neutral at Goldman
Goldman started shares of Alnylam Pharmaceuticals with a Neutral rating and $113 price target saying it prefers to wait for a more favorable entry point into the name.
December 11, 2014
16:02 EDTALNYAlnylam initiates ENDEAVOUR Phase 3 clinical trial with revusiran
Subscribe for More Information
08:02 EDTALNYAlnylam, The Medicines Co. announce initiation of Phase 1 ALN-PCSsc trial
Subscribe for More Information
December 9, 2014
12:22 EDTALNYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
06:38 EDTALNYAlnylam to host conference call
Conference call to discuss Phase 1 data from ALN-AT3, in development for the treatment of hemophilia will be held on December 9 at 8 am. Webcast Link
05:47 EDTALNYAlnylam reports poisitve initial results for ALN-AT3
Subscribe for More Information
December 8, 2014
13:07 EDTNVSNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
13:05 EDTNVSNovartis reports six-year results from Phase III ENESTnd study
Subscribe for More Information
11:30 EDTNVSLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use